- Home
- AUST vs GTBP Comparison
AUST vs GTBP Comparison
Compare AUST & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AUST | GTBP |
|---|---|---|
| Founded | 2020 | 1965 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0M | 17.7M |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | AUST | GTBP |
|---|---|---|
| Price | $1.31 | $0.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 134.8K | ★ 444.9K |
| Earning Date | 05-06-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.87 | $0.26 |
| 52 Week High | $3.92 | $1.53 |
Technical Indicators
Market Signals| Indicator | AUST | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 66.28 | 38.36 |
| Support Level | $1.27 | $0.27 |
| Resistance Level | $1.42 | $0.47 |
| Average True Range (ATR) | 0.11 | 0.02 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 94.12 | 28.45 |
Price Performance
Historical ComparisonAbout AUST Austin Gold Corp.
Austin Gold Corp is focused on the acquisition, exploration, and evaluation of mineral resource properties in the western United States of America (USA). The exploration and development of mineral projects is considered the Company's single business segment. Its projects include Kelly Creek, Lone Mountain, Stockade Mountain, Fourmile Basin, and Miller.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.